IPSEN (OTCMKTS:IPSEY) Trading Down 6.2% – Here’s What Happened

IPSEN (OTCMKTS:IPSEY) shares dropped 6.2% during mid-day trading on Tuesday . The company traded as low as $44.74 and last traded at $44.74. 256 shares changed hands during trading, a decline of 88% from the average daily volume of 2,197 shares. The stock had previously closed at $47.72.

Wall Street Analyst Weigh In

IPSEY has been the subject of several research reports. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, IPSEN has an average rating of “Hold”.

IPSEN Stock Performance

The company has a 50 day moving average price of $46.77 and a 200 day moving average price of $44.75.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).